Bayer's Fortnight of Reckoning: Cash Crunch Meets Supreme Court Hope

The coming days represent a critical convergence of legal and financial pressures for Bayer AG. As the German conglomerate navigates a significant cash flow deficit, its immediate future hinges on a pivotal hearing in Washington and a shareholder meeting that will test investor confidence.

At the heart of the financial strain is a projected free cash flow of negative €2.5 billion for 2026. This substantial shortfall is directly attributed to the immense costs of ongoing litigation, even as the company managed to slightly reduce its net financial debt to €29.8 billion by the end of 2025. Management, led by executive Sebastian Guth, insists its full-year guidance remains intact, targeting revenue between €45 and €47 billion. The firm contends that recently imposed US import tariffs on pharmaceuticals, capped at 15 percent, have already been factored into these calculations.

Simultaneously, the operational engine shows robust signs of life. The pharmaceuticals division, buoyed by five first-time approvals last year, is targeting an operational margin of 30 percent by 2030. A standout performer is the drug Kerendia, which posted a currency- and portfolio-adjusted sales increase of 88 percent. Its recent expanded EU approval for treating heart failure opens a market of millions of patients across Europe. Bayer's management has long-term peak sales ambitions exceeding €3 billion for the treatment, aiming to cement its status as a blockbuster.

The legal landscape, however, overshadows these operational gains. All eyes are on the US Supreme Court, where oral arguments in the case Durnell v. Monsanto are scheduled for April 27, 2026. The core question—whether federal law preempts state-level liability claims regarding glyphosate warning labels—could dramatically reshape Bayer's legal exposure. A favorable ruling by June would significantly reduce litigation provisions and bolster the company's settlement strategy. CEO Bill Anderson has already framed the Court's decision to hear the case as a crucial step toward regulatory clarity for the entire industry.

Should investors sell immediately? Or is it worth buying Bayer?

Parallel state-level developments add further complexity. A multi-billion dollar settlement has received preliminary approval in Missouri, while Kentucky recently became the third US state to pass legislation shielding companies from certain types of lawsuits.

This tense backdrop frames Bayer's virtual Annual General Meeting on April 24. The supervisory board has proposed an unchanged dividend of €0.11 per share and will oversee a personnel shift, with Marcel Smits and Alfred Stern nominated to replace long-standing members Paul Achleitner and Colleen Goggins. Key dates for shareholders are clustered together: the dividend ex-date also falls on April 27, with payment due on April 29.

Despite the challenges, the stock has shown remarkable resilience, gaining 5.51 percent since the start of the year and a striking 101 percent over the past twelve months. It entered this decisive period trading at €40.12. Major investment banks underscore this optimism; Goldman Sachs maintains a buy rating with a €54.50 price target, while JPMorgan confirms an "overweight" stance and a €50.00 target, praising the company's solid operational foundation.

Bayer at a turning point? This analysis reveals what investors need to know now.

The sequence of events—the shareholder meeting, the Supreme Court hearing, and the imminent quiet period ahead of quarterly results on May 12—will provide concrete signals about Bayer's capacity to sustain its recovery. The company's ability to manage its profound cash flow pressures while awaiting legal salvation will define its trajectory for the remainder of the decade.

Ad

Bayer Stock: New Analysis - 12 April

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYERS | boerse | 69132984 |